Letter to the Editor: Treatment of Covid-19 with Fisetin flavonoid nanoparticles

A novel coronavirus 2019 (Covid-19) was identified in Wuhan, China causing an outbreak of pneumonia worldwide. The first infection of the coronavirus was associated with a kind of seafood. The patient of the covid-19 pandemic was accompanied by the most common symptoms of fever, lung inflammation, dry cough, and tiredness. Researchers have found that natural flavonoid and antioxidant products such as wildly phytomedicine and anti-inflammatory drugs can play a therapeutically rolls in accelerating the recovery of the viral disease. Fisetin, a known flavonoid in fruits and vegetables, is a powerful anti-inflammatory and antioxidant. With the help of drug delivery technology, fisetin can be present in nanoparticles in a targeted manner in a short time with the minimum dose and also the least side effects to create a high degree of effectiveness in the treatment of this virus.

Keywords

Coronavirus

COVID-19

Flavonoids

Fisetin

Nanoparticles

Drug Delivery Systems

References

1.
Guo YR, Cao QD, Hong ZS, Tan YY, Chen SD, Jin HJ, e al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak-An update on the status. Mil Med Res 2020; 7: 11-20.
2.
Li H, Liu L, Zhang D, Xu J, Dai H, Tang N, et al. SARS-CoV-2 and viral sepsis: Observations and hypotheses. Lancet 2020; 395: 1517-1520.
3.
Mishra A, Kaur U, Singh A. Fisetin 8-C-glucoside as entry inhibitor in SARS CoV-2 infection: molecular modelling study. J Biomol Struct Dyn 2020; 1-10.
4.
Santana FP, Thevenard F, Gomes KS, Taguchi L, Cmara NO, Stilhano RS, et al. New perspectives on natural flavonoids on COVID19induced lung injuries. Phytother Res 2021; 35: 4988-5006.
5.
Astuti I. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): An overview of viral structure and host response. diabetes and metabolic syndrome. Clin Res Rev 2020; 14: 407-412.
6.
Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science 2020; 367: 1444-1448.
7.
Burgos-Blasco B, Gemes-Villahoz N, Santiago JL, Fernandez-Vigo JI, Espino-Paisn L, Sarri B. Hypercytokinemia in COVID-19: Tear cytokine profile in hospitalized COVID-19 patients. Exp Eye Res 2020; 200: 108253-108258.
8.
Bez-Santos YM, John SE, Mesecar AD. The SARS-coronavirus papain-like protease: Structure, function and inhibition by designed antiviral compounds. Antiviral Res 2015; 115: 21-38.
9.
Juc MM, Cysne Filho FM, de Almeida JC, Mesquita DD, Barriga JR, Dias KC, et al. Flavonoids: Biological activities and therapeutic potential. Nat Prod Res 2020; 34: 692-705.
10.
Camell CD, Yousefzadeh MJ, Zhu Y, Prata LG, Huggins MA, Pierson M, et al. Senolytics reduce coronavirus-related mortality in old mice. Science 2021; 373: eabe4832.
11.
Crane MJ, Devine S, Jamieson AM. Graphene oxide/silver nanoparticle ink formulations rapidly inhibit influenza A virus and OC43 coronavirus infection in vitro. Bio Rxiv 2021.
12.
Zhao Z, Xiao Y, Xu L, Liu Y, Jiang G, Wang W, et al. Glycyrrhizic acid nanoparticles as antiviral and anti-inflammatory agents for COVID-19 treatment. ACS Appl Mater Interfaces 2021; 13: 20995-21006.
13.
Dourado D, Freire DT, Pereira DT, Amaral-Machado L, Alencar N, de Barros AL, Egito ES. Will curcumin nanosystems be the next promising antiviral alternatives in COVID-19 treatment trials. Biomed Pharmacother 2021; 139: 111578.
14.
Neghab HK, Azadeh SS, Soheilifar MH, Dashtestani F. Nanoformulation-Based antiviral combination therapy for treatment of COVID-19. Avicenna J Med Biotechnol 2020; 12: 255-256.##.

comments